<DOC>
	<DOCNO>NCT02478333</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics ALS-008176 follow oral administration single ascend dose ALS-008176 healthy Japanese adult participant .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacokinetics ALS-008176 Healthy Japanese Adult Participants</brief_title>
	<detailed_description>This double-blind ( test experiment neither person give treatment patient know treatment patient receiving ) , placebo-controlled , randomize ( study medication assign participant chance ) single-center study ALS-008176 . The duration study approximately 6 week participant . The study consist 3 part : Screening Phase ( 28 day study commences Day 1 ) ; double-blind Treatment Phase ( single oral dose ALS-008176 placebo Day 1 fast condition ) ; Follow Phase ( 14 day study drug administration ) . All eligible participant randomly assign receive either single oral dose ALS-008176 placebo group . The planned dos escalate stepwise fashion safety tolerability precede dose find acceptable . Participants Group 1 receive ALS-008176 , 250 milligram ( mg ) placebo , Group 2 receive ALS-008176 , 500 mg placebo Group 3 receive ALS-008176 , 750 mg placebo . Study drug administer follow 10-hour overnight fast . Blood sample collect evaluation pharmacokinetics pre-dose post-dose study treatment . Pharmacokinetics ALS-008176 , ALS-008206 , ALS-008112 , metabolite ALS 008144 evaluate primarily . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>Be Japanese participant whose parent grandparents Japanese determine participant 's verbal report Each participant must sign Informed Consent Form ( ICF ) indicate understands purpose procedure require study willing participate study Participant must willing able adhere prohibition restriction specify protocol A female participant must either : 1 . Not childbearing potential : postmenopausal [ great ( &gt; ) 45 year age amenorrhea least 2 year , age amenorrhea least 6 month serum follicle stimulate hormone ( FSH ) level &gt; 40 International Units ( IU ) / liter ( L ) ( confirm Screening postmonopausal woman ) ] OR 2 . Permanently sterilize ( eg , bilateral tubal occlusion [ include tubal ligation procedure consistent local regulation ] , hysterectomy , bilateral salpingectomy , bilateral oophorectomy ) otherwise incapable become pregnant , OR c. If childbearing potential heterosexually active , practice effective method birth control entry agree continue use two effective method contraception throughout study least 30 day receive study drug Participant must nonsmoker least one month prior screen Participant history current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , hepatic renal insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness Investigator considers exclude participant could interfere interpretation study result Participant past history heart arrhythmia ( extrasystoli , tachycardia rest ) , history risk factor Torsade de Pointes syndrome ( eg , hypokalemia , family history long QT Syndrome ) Participant creatinine clearance low 70 millilitre ( mL ) /min Participant take disallowed therapy note protocol , Prestudy Concomitant Therapy plan study drug Participant history human immunodeficiency virus ( HIV ) antibody positive , test positive HIV screening</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>ALS-008176</keyword>
	<keyword>Japanese adult participant</keyword>
</DOC>